Jeremy P. Springhorn net worth and biography

Jeremy Springhorn Biography and Net Worth

Director of uniQure

Jeremy Springhorn, Ph.D. has served as a member of our Board since September 2017. From April 2021 until January 2026, Dr. Springhorn was Chief Executive Officer of Nido Biosciences, a developer of small molecule therapeutics. Prior to taking his position at Nido, Dr. Springhorn was Chief Business Officer of Syros Pharmaceuticals, Inc. (Nasdaq: SYRS) from November 2017 until April 2021. Prior to taking his position at Syros, Dr. Springhorn served as Partner, Corporate Development at Flagship Pioneering from March 2015 until June 2017 where he worked with VentureLabs in helping companies in various strategic and corporate development capacities, creating next generation startups, and working with Flagship’s Corporate Limited Partners. Prior to joining Flagship, Dr. Springhorn was one of the original scientists at Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and was one of the original inventors of the drug Soliris®. At Alexion Pharmaceuticals, Dr. Springhorn was Vice President of Corporate Strategy and Business Development from 2006 until March 2015. Dr. Springhorn started at Alexion in 1992, where he served in various leadership roles in R&D before switching to Business Development in 2006. Prior to 1992, Dr. Springhorn received his Ph.D. from Louisiana State University Medical Center in New Orleans and his BA from Colby College.

What is Jeremy P. Springhorn's net worth?: The estimated net worth of Jeremy P. Springhorn is at least $1.21 million as of June 11th, 2026. Dr. Springhorn owns 43,251 shares of uniQure stock worth more than $1,205,405 as of June 16th. This net worth evaluation does not reflect any other assets that Dr. Springhorn may own. Learn More about Jeremy P. Springhorn's net worth.
How do I contact Jeremy P. Springhorn?: The corporate mailing address for Dr. Springhorn and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Jeremy P. Springhorn's contact information.
Has Jeremy P. Springhorn been buying or selling shares of uniQure?: During the last ninety days, Jeremy P. Springhorn has sold $53,930.58 in uniQure stock. Most recently, Jeremy P. Springhorn sold 1,993 shares of the business's stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a transaction totalling $53,930.58. Following the completion of the sale, the director now directly owns 43,251 shares of the company's stock, valued at $1,170,372.06. Learn More on Jeremy P. Springhorn's trading history.
Who are uniQure's active insiders?: uniQure's insider roster includes Walid Abi-Saab (Insider), Madhavan Balachandran (Director), Pierre Caloz (COO), Ricardo Dolmetsch (Insider), Robert Gut (Director), Rachelle Jacques (Director), Matthew Kapusta (CEO), Jack Kaye (Director), Christian Klemt (CFO), Alexander Kuta, III (VP), David Meek (Director), Leonard Post (Director), Jeannette Potts (Insider), and Jeremy Springhorn (Director). Learn More on uniQure's active insiders.
Are insiders buying or selling shares of uniQure?: In the last twelve months, insiders at the biotechnology company sold shares 33 times. They sold a total of 503,920 shares worth more than $16,445,021.99. The most recent insider tranaction occured on June, 11th when Director Robert Gut sold 2,726 shares worth more than $73,765.56. Insiders at uniQure own 4.7% of the company. Learn More about insider trades at uniQure.
Information on this page was last updated on 6/11/2026.

Jeremy P. Springhorn Insider Trading History at uniQure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/11/2026	Sell	1,993	$27.06	$53,930.58	43,251
6/20/2025	Sell	2,112	$14.45	$30,518.40	37,694
1/28/2019	Sell	1,210	$31.32	$37,897.20	6,812

Jeremy P. Springhorn Buying and Selling Activity at uniQure

uniQure Company Overview

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Today's Range

Now: $27.87

$27.26

$28.50

50 Day Range

MA: $22.74

$15.38

$29.88

2 Week Range

Now: $27.87

$8.73

$71.50

Volume

1,091,406 shs

Average Volume

1,314,325 shs

Market Capitalization

$1.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98